Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
MarineMax Q4 net loss widens to $13.04 million

MarineMax Q4 net loss widens to $13.04 million

BitgetBitget2026/11/04 11:45
  • MarineMax's FY26 fourth-quarter net loss attributable to shareholders widened to $13.04 million.
  • Revenue fell 6% year over year to $520.14 million, primarily due to lower boat sales.
  • Gross margin rose to 37.4%, driven by improved boat profitability and greater contributions from higher-margin businesses.
  • Safe Harbor's acquisition for $53.00 per share in cash is expected to close by the end of 2026.
  • The pending acquisition prompted management to withhold FY27 financial guidance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marinemax Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611040645BIZWIRE_USPR_____20261104_BW264116) on November 04, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss